To develop and deliver innovative treatments for brain disease, we work with a range of stakeholders. These include healthcare professionals (HCPs) and healthcare organisations (HCOs) as well as patient organisations (POs), other relevant decision makers (ORDMs) and the public. We may collaborate on research, clinical development, exchange of scientific information, and educational activities.
These interactions are well-regulated by the national laws and industry association regulations that we integrate into our working processes, training and guidance.
We are committed to transparency and our disclosed information follows the current regulations from the industry associations we have joined, such as the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Association of the British Pharmaceutical Industry (ABPI).
As a member of the ABPI, we abide by the requirements for disclosing details of payments and other benefits in kind made by industry to HCPs, HCOs, ORDMs, POs and the public in the UK.
We believe that the relationship between the pharmaceutical industry and healthcare professionals (HCPs) and healthcare organisations (HCOs) plays a vital role in helping to improve patient outcomes. At Lundbeck UK, we engage with stakeholders to provide advice and support through the development and delivery of medical education services on the appropriate medicines to help improve on patient outcomes.
On occasion, it is appropriate that fees are paid to health professionals to reimburse them for their time and expertise in delivering on these services. At the core of the relationship is sharing knowledge to improve outcomes for patients. We want to ensure that patients and others have confidence that this relationship is open and transparent.
This information can be found on the database Disclosure UK.
If you are a healthcare professional and have a query in relation to transparency or a transfer of value, please contact us here.
Lundbeck UK have made various donations and sponsorships to patient organisations to support the improvement of patient outcomes. Please see below for links to our disclosures to patient organisations.
Please see below for links to our disclosures to members of the public, including patients and journalists.
We pursue our business purpose guided by several pillars and our Code of Conduct.
Our policy for scientific publications and responsible clinical data sharing.
We see patients as people and are committed to supporting the person behind the disease.
UK-NOTPR-1536 | June 2023